Likewise, in a Japanese study conducted in 9,800 patients treated with nivolumab and ~400 patients treated with ipilimumab, the complication of myasthenia gravis (MG) has been observed to occur more frequently in patients treated with nivolumab (anti-PD-1) than in those treated with ipilimumab (anti-CTLA-4). The gene discussed is CTLA4; the disease is myasthenia gravis.